CSPC Pharmaceutical Group Limited: Breast Neoplasms trials

The registry lists 22 Breast Neoplasms studies with CSPC Pharmaceutical Group Limited as lead sponsor. 11 are open to participants now and 0 have results posted.

Phase 1 4Phase 2 8Phase 3 9Phase 4 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of JSKN003 Versus Trastuzumab in Combination With Pertuzumab and Docetaxel as First-Line Treatment for HER2-Positive Recurrent or Metastatic Breast CancerNot yet recruitingNCT07545044Phase 2
• A Phase III Study of SYS6010 Versus Chemotherapy in HER2-Negative, EGFR-Positive Recurrent or Metastatic Breast CancerNot yet recruitingNCT07406542Phase 3
• A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast CancerNot yet recruitingNCT06941142Phase 1
• Sirolimus for Injection (Albumin-bound) Combined With Fulvestrant for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Previously Treated With CDK4/6 InhibitorsNot yet recruitingNCT06929325Phase 3
• JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast CancerRecruitingNCT06846437Phase 3
• Clinical Trial of SYS6010±SYH2051 Versus Chemotherapy in Advanced Breast Cancer and Other Solid TumorsNot yet recruitingNCT06775236Phase 1/2
• A Study to Evaluate the Efficacy and Safety in Subjects With Advanced Breast Cancer Treated With SYHX2011Not yet recruitingNCT06354114Phase 2
• DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast CancerRecruitingNCT06313086Phase 3
• DP303c in Patients With HER2-positive Advanced Breast CancerNot yet recruitingNCT05901935Phase 3
• Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer.RecruitingNCT05838066Phase 3
• Study to Evaluate the Efficacy and Safety of SYSA1901 vs. Perjeta® of HER2-Positive Breast CancerRecruitingNCT05720026Phase 3
• Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard TherapyActive, not recruitingNCT06957379Phase 2
• A Study to Evaluate the Efficacy and Safety in Patients With Advanced Breast Cancer Treated With SYHX2011 Compared to Paclitaxel for Injection (Albumin-bound)Status unknownNCT05753865Phase 3
• DP303c in Patients With HER2-positive Unresectable Locally Advanced, Relapsed, or Metastaticbreast CancerStatus unknownNCT05334810Phase 2
• A Pharmacokinetic Comparison Study of SYHX2011 and Abraxane® in Patients With Advanced Breast CancerStatus unknownNCT05274893Phase 1
• A Study to Evaluate the Efficacy and Safety of SG001 in Combination With Nab-Paclitaxel in Patients With Advanced Triple-Negative Breast Cancer (TNBC)Status unknownNCT05068141Phase 2
• A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced HER2 Negative Breast CancerTerminatedNCT04927481Phase 2
• Study of Irinotecan Liposome Injection in Patients With Advanced Breast CanceCompletedNCT04728035Phase 1
• A Study of First-line JS001 and Nab-paclitaxel Versus Palcelbo and Nab-Paclitaxel in Participants With Advanced Recurrent or Metastatic TNBCSuspendedNCT03777579Phase 3
• PEG-rhG-CSF in Patients With Breast Cancer Receiving Chemotherapy to Prevent NeutropeniaCompletedNCT02805205Phase 4
• PEG-rhG-CSF in Patients With Breast Cancer Receiving ChemotherapyCompletedNCT02805153Phase 4
• A Study of Mitoxantrone Hydrochloride Liposome Injection in Advanced Recurrent or Metastatic Breast CancerStatus unknownNCT02596373Phase 2